Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
Background and objectives: This study aimed to compare the efficacy of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and brigatinib in the treatment of advanced non-small-cell lung cancer (NSCLC) with ALK rearrangements based on real-world data. D...
Saved in:
Main Authors: | Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah Young Shin, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Jeong Uk Lim, Chang Dong Yeo |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-02-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359251316200 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of brigatinib following alectinib-induced-pneumonitis: Case report
by: Blerina Resuli, et al.
Published: (2025-01-01) -
Molecular characterization of Pseudomyxoma peritonei with single-cell and bulk RNA sequencing
by: Ye Jin Ha, et al.
Published: (2025-02-01) -
Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review
by: Mingyue Wang, et al.
Published: (2025-02-01) -
Classical eikonal from Magnus expansion
by: Joon-Hwi Kim, et al.
Published: (2025-01-01) -
Fucoxanthin Inhibits the NMDA and AMPA Receptors Through Regulating the Calcium Response on Substantia Gelatinosa Neurons of the Trigeminal Subnucleus Caudalis in Juvenile Mice
by: Nhung Ha Thuy Le, et al.
Published: (2025-01-01)